Statistics from Altmetric.com
Contributors IR and MBD wrote the initial drafts of the commentary. CTV and BFV edited the initial draft and provided information on chemokine structure to the commentary.
Competing interests The use of recombinant CXCL12 as an antimetastatic drug is protected by US Patent 8 404 640 to MBD. BFV and MBD as co-founders of Protein Foundry, LLC, a manufacturer of molecular grade chemokines for use in biomedical research.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.